v3.20.4
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jun. 25, 2018
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenues [Abstract]        
Total net revenue   $ 444,448 $ 408,830 $ 276,741
Cost of revenue   258,555 211,994 149,476
GROSS PROFIT   185,893 196,836 127,265
Operating expenses:        
General and administrative   143,794 127,993 84,822
Research and development   8,229 8,487 3,001
Sales and marketing   47,862 47,350 29,402
Total operating expenses   199,885 183,830 117,225
(LOSS) INCOME FROM OPERATIONS   (13,992) 13,006 10,040
Interest expense, net   7,019 3,713 6,230
Other (income) expense, net   (11,861) 4,630 (14)
Loss on extinguishment of debt   1,400 1,018 0
Loss on termination of cash flow hedge   3,506 0 0
(Loss) income before taxes   (14,056) 3,645 3,824
Income tax (benefit) expense   (18,228) (4,361) 1,184
NET INCOME   4,172 8,006 2,640
Deemed dividends on preferred stock and amortization of beneficial conversion feature   0 0 5,627
Gain on redemption of preferred stock $ (9,100) 0 0 (9,075)
NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS   $ 4,172 $ 8,006 $ 6,088
Earnings Per Share, Basic and Diluted [Abstract]        
Basic (in dollars per share)   $ 0.04 $ 0.08 $ 0.07
Diluted (in dollars per share)   $ 0.04 $ 0.08 $ 0.07
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING        
Basic (in shares)   108,579 100,470 85,618
Diluted (in shares)   111,794 103,615 91,568
Clinical Services        
Revenues [Abstract]        
Total net revenue   $ 382,337 $ 361,161 $ 241,873
Pharma Services        
Revenues [Abstract]        
Total net revenue   $ 62,111 $ 47,669 $ 34,868

Source